Lipocine (LPCN) Expected to Announce Earnings on Thursday

Lipocine (NASDAQ:LPCN) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Lipocine to post earnings of ($0.56) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). The firm had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.00 million.

Lipocine Stock Down 2.2%

Shares of LPCN opened at $2.69 on Thursday. The company has a market capitalization of $14.58 million, a P/E ratio of -3.09 and a beta of 1.29. The firm has a 50 day moving average of $2.95 and a 200 day moving average of $3.13. Lipocine has a twelve month low of $2.65 and a twelve month high of $6.17.

Analysts Set New Price Targets

Several brokerages recently weighed in on LPCN. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Wednesday, October 8th. Alliance Global Partners raised shares of Lipocine to a “strong-buy” rating in a research report on Monday, August 11th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Lipocine in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.